Cresud: Fiscal Q4 Earnings Snapshot

By The Associated Press
September 8, 2026 | 9:16 AM

BUENOS AIRES, Argentina (AP) — BUENOS AIRES, Argentina (AP) — Cresud Sociedad Anonima Comercial, Inmobiliaria, Financiera y Agropecuaria (CRESY) on Tuesday reported earnings of $39.5 million in its fiscal fourth quarter.

The Buenos Aires, Argentina-based company said it had net income of 57 cents per share.

The agricultural company posted revenue of $293.8 million in the period.

For the year, the company reported profit of $125.4 million, or $1.91 per share. Revenue was reported as $975.7 million.

_____

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on CRESY at https://www.zacks.com/ap/CRESY

Cyclospora outbreak followed years of declining FDA foreign inspections

By The Associated Press
September 8, 2026 | 9:28 AM

WASHINGTON (AP) — A nationwide outbreak of cyclospora tied to contaminated lettuce has heightened safety concerns about imported food, while underscoring a longer-term trend: U.S. regulators are conducting fewer international inspections to catch contaminated produce before it lands on American plates. Food and Drug Administration inspections of foreign food sites — including the Mexican farm linked to the ongoing outbreak — are down nearly 35% since 2019, the year before the COVID-19 pandemic, according to agency records reviewed by The Associated Press. The pandemic kicked off a wave of retirements and departures among FDA inspectors that continues to this day. Even before COVID-19, the agency had long failed to hit its congressionally mandated targets for international inspections. And recent staffing cuts, reorganizations and other upheavals under President Donald Trump could mean even fewer inspections in the years ahead, according to former senior FDA officials. “When you look at the numbers of inspections balanced against the responsibility of the FDA — in terms of all the firms domestically and internationally under its oversight — the agency just can’t achieve what is required,” said Michael Rogers, who spent nearly 35 years in various inspection roles within the agency. He added that FDA continues to do many things “very well with limited resources.”

Related Stories